Hikma Pharmaceuticals, a U.K.-based company, has announced a $1 billion investment to expand its manufacturing and research and development (R&D) capabilities in the United States. The investment will focus on facilities in Ohio and New Jersey and aims to reduce reliance on China by producing a broad range of life-saving medicines domestically. This move aligns Hikma with other branded drugmakers increasing their U.S. investments. Separately, Biogen has revealed a $2 billion investment to expand and modernize its manufacturing operations in North Carolina’s Research Triangle Park. The funds will enhance antisense drug production, add fill-finish lines, and incorporate artificial intelligence and automation technologies. Biogen currently operates eight facilities in North Carolina.